Markets

Endo (ENDP) Restructures Branded Pharmaceutical Unit (revised)

Shutterstock photo

Endo International plcENDP announced that it has begun restructuring its corporate and branded pharmaceutical R&D functions in Malvern, PA and Chestnut Ridge, NY.

Shares of Endo have underperformed the Zacks classified industry in the past one year. Specifically, the stock plunged 79.4% during this period in comparison to a decline of 10.6% for the industry.

Shares of Endo have underperformed the Zacks classified Medical-Drugs industry in the past one year. Specifically, the stock plunged 79.4% during this period in comparison to a decline of 10.6% for the industry.

The initiative aims to better align the corporate and branded pharmaceutical R&D functions in size and scope with the recently restructured generics and branded pharmaceutical business units in the U.S.

These initiatives are expected to provide greater efficiencies and corresponding cost savings.

These restructuring actions are likely to reduce the company's headcount by approximately 90 full-time positions and result in pre-tax cost savings of $40 million to $50 million on an annual run rate basis by the fourth quarter of 2017.

We remind investors that Endo completed the integration, product portfolio rationalization and restructuring of its generics business segment in 2016. Thereafter, Endo introduced a unified operating model that streamlined its global supply chain organization to boost its Branded and Generics businesses. The company has eliminated its pain field sales force in the branded segment in the U.S.

We note that the company's generic segment is under pressure given the challenging competitive landscape and pricing pressures. Consequently, Endo expects to invest a portion of these cost savings in the company's core product franchises and new product development programs for both the branded and generics business segments.

Endo currently carries a Zacks Rank #5 (Strong Sell). Shares are under tremendous pressure due to concerns related to the ongoing investigations and the present focus on drug pricing. Concerns relating to pricing are expected to remain a major overhang on the company's shares.

Endo International PLC Price and Consensus

Endo International PLC Price and Consensus | Endo International PLC Quote

Key Picks

Some better-ranked stocks in the health care sector include Sucampo Pharmaceuticals SCMP , Anika Therapeutics ANIK and Sunesis Pharmaceuticals SNSS . While Sucampo and Sunesis sport a Zacks Rank #1 (Strong Buy), Anika carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .

Sunesis' loss estimates narrowed 5.06% and 8.80% for 2016 and 2017, respectively, over the past 60 days. The company recorded a positive earnings surprise in three of the last four quarters, the average being 0.54%.

Anika's earnings estimates for 2016 and 2017 were up 3.9% and 0.5%, respectively, over the last 60 days. The company recorded a positive earnings surprise in each of the last four quarters, the average being 33.1%. Its share price was up 37.2% in the past one year.

Sucampo's earnings estimates were stable at $1.22 for 2016 but have increased from $1.58 to $1.74 for 2017 over the last 60 days. The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 35.5%.

The Best Place to Start Your Stock Search

Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks - absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>

(We are reissuing this article to correct a mistake. The original article, issued Friday, January 27, 2017, should no longer be relied upon.)

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Anika Therapeutics Inc. (ANIK): Free Stock Analysis Report

Endo International PLC (ENDP): Free Stock Analysis Report

Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis Report

Sunesis Pharmaceuticals, Inc. (SNSS): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ANIK SNSS ENDP

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More